Prescription drug · BLA
NYPOZI txid (filgrastim-txid) NDC 72374-102
Filgrastim 480 ug/480ug · Injection · Intravenous, Subcutaneous · Tanvex BioPharma USA, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72374-102-01 | 72374010201 | 1 SYRINGE, GLASS in 1 CARTON (72374-102-01) / 480 ug in 1 SYRINGE, GLASSMarketed from Sep 23, 2025 | |
| 72374-102-10 | 72374010210 | 10 SYRINGE, GLASS in 1 CARTON (72374-102-10) / 480 ug in 1 SYRINGE, GLASSMarketed from Sep 23, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- NYPOZI txidSuffix: txid
- Generic name (nonproprietary)
- filgrastim-txid
- Active ingredients
- Filgrastim — 480 ug/480ug
- Dosage form
- Injection
- Route
- Intravenous, Subcutaneous
- Labeler
- Tanvex BioPharma USA, Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761126
- Marketing start
- Listing expires
- Other FDA classes
- Granulocyte Colony-Stimulating Factor (Chemical structure)Increased Myeloid Cell Production (Physiologic effect)
- Identifiers
- Product ID 72374-102_23d9f1d4-c25a-45fb-8095-986c659cb532SPL ID 23d9f1d4-c25a-45fb-8095-986c659cb532SPL set ID 89092bb8-6a20-e23e-e053-2a95a90aa750RxCUI 2700369, 2700376, 2700378, 2700379UNII PVI5M0M1GW
- Pharmacologic class
- Leukocyte Growth Factor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N472374010201followed by a unit qualifier and the quantityPackage 72374-0102-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT…
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 761126
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| NYPOZI txidfilgrastim-txid | Filgrastim 300 ug/300ug | InjectionIntravenous, Subcutaneous | Tanvex BioPharma USA, Inc. | 72374-101 |
| Nypozifilgrastim-txid | Filgrastim 480 ug/480ug | InjectionIntravenous, Subcutaneous | Cipla USA Inc. | 69097-429 |
| Nypozifilgrastim-txid | Filgrastim 300 ug/300ug | InjectionIntravenous, Subcutaneous | Cipla USA Inc. | 69097-430 |